LGLuca Gobbi

Luca Gobbi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luca Gobbi has a total of 221 co-authors. Here are the top co-authors by number of shared publications:

  • Michael Honer

    Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd

    11 shared publications
  • Uwe Grether

    Roche Pharma Research and Early Development Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 Basel 4070 Switzerland

    7 shared publications
  • Andreas Topp

    F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124

    6 shared publications
  • Ludovic Collin

    F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124

    6 shared publications
  • Bernd Kuhn

    Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel F. Hoffmann‐La Roche AG Basel 4070 Switzerland

    5 shared publications
  • Matthias Beat Wittwer

    Roche Pharma Research and Early Development Roche Innovation Center Basel F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124 Basel 4070 Switzerland

    5 shared publications

Latest Publications

  • Translational Application of the Five-Star Matrix for the Structure-Guided Optimization of a Bicyclopiperazine DEL Hit into Bcpz 1.5: A Potent Monoacylglycerol Lipase Inhibitor with Functional Inhibition in Human Brain Homogenate and Efficacy in Neuroinflammatory Models

    by Benjamin Brennecke, Louise Plais, Benoit Hornsperger, Martin Binder, Christian Bartelmus, Markus BürKler, Fionn O’HAra, Carsten Kroll, Satoshi Tsuchiya, Buelent Kocer, et al.

    Monoacylglycerol lipase (MAGL) is a promising therapeutic target for neuroinflammatory conditions. We have previously reported on MAGLi 432, a reversible MAGL inhibitor with activity in mouse models of neuroinflammation. In this full account, we report on the structure-guided optimization of a bicyclopiperazine (Bcpz) DEL hit into potent, selective and brain-penetrant reversible MAGL inhibitor 1.5 (MAGLi 432), guided by the “Five-Star Matrix” translational framework. Compound 1.5 combines excellent MAGL potency (IC50 = 3.2 nM) and selectivity over other serine hydrolases with favorable pharmacokinetic properties, including a 5.7 h half-life after oral administration in male Wistar rats, and CNS drug-like potential. Furthermore, as previously reported, the compound demonstrated robust brain penetration and efficacy in preclinical mouse models of neuroinflammation correlating with inhibition of MAGL activity in mouse and human brain homogenate. This work highlights the power of combining DEL screening and SBDD with the Five-Star Matrix to deliver drug-like candidates for neuroinflammatory disorders.

  • Discovery of the First Brain-Penetrant Radioligands for Visualizing the GABA Transporter 1 (GAT-1): Synthesis, In Vitro Screening, and In Vivo Evaluation in Nonhuman Primates

    by Jiwei Gu, Chao Wang, Luca Gobbi, Michael Honer, Ming-Qiang Zheng, Paul Gravel, Hong Gao, Li Zhang, Jim Ropchan, Nabeel Nabulsi, et al.

    The γ-aminobutyric acid (GABA) system regulates neuronal excitability in the central nervous system and is implicated in multiple neuropsychiatric and neurodegenerative disorders. GABA transporter 1 (GAT-1) is a key regulator of synaptic GABA levels but has been difficult to image in vivo due to the lack of blood-brain barrier (BBB)-permeable radioligands for positron emission tomography (PET). Here, we report the design, synthesis, and evaluation of novel tiagabine-based derivatives as brain-penetrant radioligands for GAT-1. Screening of 105 compounds identified four candidates (GATT-31, GATT-34, GATT-39, and GATT-44) with high GAT-1 affinity, appropriate lipophilicity, and low P-glycoprotein efflux liability. These ligands were radiolabeled via copper-mediated 18F-radiofluorination. PET imaging in nonhuman primates demonstrated good brain uptake of the radioligands. Among them, [18F]GATT-44 appeared to be the most promising with good metabolic stability and high GAT-1 binding specificity. The discovery of BBB-penetrating radioligands enables, for the first time, in vivo imaging of GAT-1 in the brain.

  • Open Access

    Pretargeted Immuno-PET Enables Monoclonal Antibody Imaging Beyond the Blood–Brain Barrier

    by Tobias Gustavsson, Thomas Kustermann, Lars Hvass, Thomas E. Wuensche, Anne Skovsbo Clausen, Sophie Stotz, Vladimir Shalgunov, Sara Lopes van Den Broek, Gitte M. Knudsen, Blanca Aldana, et al.

    Pretargeted PET imaging offers a powerful approach to improve nuclear imaging contrast and reduce systemic radiation exposure, yet its application in the brain has been limited by the blood-brain barrier (BBB). Here, we demonstrate, for the first time, successful pretargeted PET imaging of a brain target enabled by a bispecific antibody engineered for transferrin receptor-mediated BBB transcytosis. By combining this brain shuttle with a novel 18F-labeled tetrazine, we achieve specific, quantifiable detection of brain-localized Aβ aggregates, validated through PET imaging and histological analysis. This proof-of-concept establishes a versatile, noninvasive imaging platform with broad potential for assessing biologic drug candidates and CNS targets previously considered intractable.


  • Tritium-Labeled Compounds in PET Tracer Discovery? A Case Study from Roche’s Internal Monoacylglycerol Lipase Program

    by Martin R. Edelmann, Luca C. Gobbi, Svenja Schmalzbauer, Jennifer Beck, Mathias C. Müller, Jean-Christophe Hau, Sylwia Huber, Achi Haider, Matthias B. Wittwer, Anto Pavlovic, et al.

    The discovery and development of PET tracers is a complex and costly process requiring direct access to 11C or 18F, radiochemistry infrastructure, as well as an imaging facility equipped with PET tomographs. In the absence of access to a fully equipped PET center facility, a valid alternative for the selection of promising PET tracer candidates is the use of tritium as a surrogate radioisotope in the early stages of development. Tritium-labeled compounds enable detailed binding or displacement assays on tissues and ex vivo radioligand performance assessments, such as rodent experiments, while offering unique advantages including a long half-life and superior spatial resolution. Furthermore, the radiation safety requirements for handling tritium-labeled compounds are less stringent compared with those needed for working with short-lived PET nuclides, such as 11C or 18F, due to the lower energy emissions of tritium. Candidates are selected based on critical attributes, including low half-maximal inhibitory concentration (IC50), brain penetration, and binding to target proteins, ensuring optimal properties for PET imaging. This approach minimizes reliance on a specialized infrastructure while accelerating the identification and optimization of radioligand candidates. As an example, to illustrate this workflow using tritiated compounds, an internal program targeting monoacylglycerol lipase (MAGL) in the CNS is presented. From a pool of 617 in-house MAGL inhibitors, five compounds were selected for tritium labeling and evaluated alongside literature-reported PET tracers. Among the newly synthesized ligands, compound 9 demonstrated a favorable pharmacological profile, while autoradiography experiments highlighted superior properties in the chemotype of T-401, originating from the literature. This study reports on the synthesis and characterization of tritium-labeled MAGL ligands as critical steps in PET tracer development. Promising candidates identified in this workflow will subsequently be handed over to PET centers for further evaluation in imaging applications, bridging preclinical research with clinical translation.


  • Open Access

    Efficacy of repeated pronations in patients affected by COVID-19-related acute respiratory distress syndrome: think it twice!

    by Andrea Sica, Luca Gobbi, Daniele Bellantonio, Silvia Passero, Lorenzo Viola

    Prone position is widely used to ameliorate gas exchange in severe COVID-19-related ARDS (CARDS), through its beneficial effects on shunt and dead space. However, the effectiveness of repeated pronation has never been explored in this category of patients. We then retrospectively analyzed the changes of the alveolar-arterial oxygen gradient (A-aO2grad), as shunt index, and the ratio EtCO2/paCO2 ratio, as dead space index, during repeated pronation cycles in 7 patients with CARDS admitted to our Intensive Care Unit. The A-aO2grad decreased significantly more during the first pronation than the second (-43.6% vs. -12.2% - p0.008) and, similarly, the improvement was maintained only after the first supination (-26.2% vs. +9% - p0.04). The EtCO2/paCO2 ratio showed similar behavior but did not achieve statistical significance. Considering our findings, with the inherent limitations of the study, since pronation entails risks for the patient, as well as requiring a lot of effort from the nursing staff, further caution appears to be necessary in indicating pronation.

  • Development of a Highly Selective NanoBRET Probe to Assess MAGL Inhibition in Live Cells

    by Thais Gazzi, Benjamin Brennecke, Valentas Olikauskas, Remo Hochstrasser, Haiyan Wang, Suzan Keen Chao, Kenneth Atz, Yelena Mostinski, Andreas Topp, Dominik Heer, et al.


  • Open Access

    Development of a Highly Selective NanoBRET Probe to Assess MAGL Inhibition in Live Cells

    by Thais Gazzi, Benjamin Brennecke, Valentas Olikauskas, Remo Hochstrasser, Haiyan Wang, Suzan Keen Chao, Kenneth Atz, Yelena Mostinski, Andreas Topp, Dominik Heer, et al.

    Cell‐free enzymatic assays are highly useful tools in early compound profiling due to their robustness and scalability. However, their inadequacy to reflect the complexity of target engagement in a cellular environment may lead to a significantly divergent pharmacology that is eventually observed in cells. The discrepancy that emerges from properties like permeability and unspecific protein binding may largely mislead lead compound selection to undergo further chemical optimization. We report the development of a new intracellular NanoBRET assay to assess MAGL inhibition in live cells. Based on a reverse design approach, a highly potent, reversible preclinical inhibitor was conjugated to the cell‐permeable BODIPY590 acceptor fluorophore while retaining its overall balanced properties. An engineered MAGL‐nanoluciferase (Nluc) fusion protein provided a suitable donor counterpart for the facile interrogation of intracellular ligand activity. Validation of assay conditions using a selection of known MAGL inhibitors set the stage for the evaluation of over 1’900 MAGL drug candidates derived from our discovery program. This evaluation enabled us to select compounds for further development based not only on target engagement, but also on favorable physicochemical parameters like permeability and protein binding. This study highlights the advantages of cell‐based target engagement assays for accelerating compound profiling and progress at the early stages of drug discovery programs.


  • Structure-Guided Discovery of cis-Hexahydro-pyrido-oxazinones as Reversible, Drug-like Monoacylglycerol Lipase Inhibitors

    by Bernd Kuhn, Martin Ritter, Benoit Hornsperger, Charles Bell, Buelent Kocer, Didier Rombach, Marius D. R. Lutz, Luca Gobbi, Martin Kuratli, Christian Bartelmus, et al.

    Monoacylglycerol lipase (MAGL) is a key enzyme involved in the metabolism of the endogenous signaling ligand 2-arachidonoylglycerol, a neuroprotective endocannabinoid intimately linked to central nervous system (CNS) disorders associated with neuroinflammation. In the quest for novel MAGL inhibitors, a focused screening approach on a Roche library subset provided a reversible benzoxazinone hit exhibiting high ligand efficiency. The subsequent design of the three-dimensional cis-hexahydro-pyrido-oxazinone (cis-HHPO) moiety as benzoxazinone replacement enabled the combination of high MAGL potency with favorable ADME properties. Through enzymatic resolution an efficient synthetic route of the privileged cis-(4R,8S) HHPO headgroup was established, providing access to the highly potent and selective MAGL inhibitor 7o. Candidate molecule 7o matches the target compound profile of CNS drugs as it achieves high CSF exposures after systemic administration in rodents. It engages with the target in the brain and modulates neuroinflammatory processes, thus holding great promise for the treatment of CNS disorders.


  • Novel OGA PET Tracer with Improved Properties and Potential for Translation to Clinical Application

    by Antonia F. Stepan, Luca C. Gobbi

    Article published online: 14 October 2023 © 2023. Thieme. All rights reserved Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Evaluation of [18F]RoSMA-18-d6 as a CB2 PET Radioligand in Nonhuman Primates

    by Achi Haider, Lu Wang, Luca Gobbi, Yinlong Li, Ahmad Chaudhary, Xin Zhou, Jiahui Chen, Chunyu Zhao, Jian Rong, Zhiwei Xiao, et al.

    The cannabinoid type 2 receptor (CB2) has been implicated in a variety of central and peripheral inflammatory diseases, prompting significant interest in the development of CB2-targeted diagnostic and therapeutic agents. A validated positron emission tomography (PET) radioligand for imaging CB2 in the living human brain as well as in peripheral tissues is currently lacking. As part of our research program, we have recently identified the trisubstituted pyridine, [18F]RoSMA-18-d6, which proved to be highly suitable for in vitro and in vivo mapping of CB2 in rodents. The aim of this study was to assess the performance characteristics of [18F]RoSMA-18-d6 in nonhuman primates (NHPs) to pave the way for clinical translation. [18F]RoSMA-18-d6 was synthesized from the respective tosylate precursor according to previously reported procedures. In vitro autoradiograms with NHP spleen tissue sections revealed a high binding of [18F]RoSMA-18-d6 to the CB2-rich NHP spleen, which was significantly blocked by coincubation with the commercially available CB2 ligand, GW405833 (10 μM). In contrast, no specific binding was observed by in vitro autoradiography with NHP brain sections, which was in agreement with the notion of a CB2-deficient healthy mammalian brain. In vitro findings were corroborated by PET imaging experiments in NHPs, where [18F]RoSMA-18-d6 uptake in the spleen was dose-dependently attenuated with 1 and 5 mg/kg GW405833, while no specific brain signal was observed. Remarkably, we observed tracer uptake and retention in the NHP spinal cord, which was reduced by GW405833 blockade, pointing toward a potential utility of [18F]RoSMA-18-d6 in probing CB2-expressing cells in the bone marrow. If these observations are substantiated in NHP models of enhanced leukocyte proliferation in the bone marrow, [18F]RoSMA-18-d6 may serve as a valuable marker for hematopoietic activity in various pathologies. In conclusion, [18F]RoSMA-18-d6 proved to be a suitable PET radioligand for imaging CB2 in NHPs, supporting its translation to humans.